Targeting a Key Enzyme Could Reverse Early Parkinson's Effects
- Stanford Medicine published on July 1, 2025, a study showing that feeding a kinase inhibitor to mice reversed effects of overactive LRRK2 in Parkinson's disease.
- The research examined a specific mutation that leads to excessive activity of the LRRK2 enzyme, which interferes with neuron signaling by causing striatal cells to lose their primary cilia.
- Mice consuming the inhibitor for three months restored primary cilia in affected neurons, normalizing hedgehog signaling and initial dopamine nerve ending recovery.
- Suzanne Pfeffer described the results as "astounding" and said findings suggest treatment might improve, not just stabilize, symptoms if started early in patients.
- Multiple clinical trials of LRRK2 inhibitors are underway, and the team plans to test if this treatment helps other Parkinson's types and neurodegenerative diseases.
13 Articles
13 Articles


Parkinson’s reversal? One drug brings dying brain cells back to life
Stanford researchers discovered that dialing down an overactive enzyme, LRRK2, can regrow lost cellular “antennae” in key brain cells, restoring vital dopamine communication and neuroprotective signals in a mouse model of genetic Parkinson’s. After three months on the LRRK2-blocking drug MLi-2, damaged circuits revived and early signs of neuronal recovery emerged, hinting that timely treatment could not only halt but reverse disease progression—…
Targeting a key enzyme could reverse early Parkinson's effects
Putting the brakes on an enzyme might rescue neurons that are dying due to a type of Parkinson's disease that's caused by a single genetic mutation, according to a new Stanford Medicine-led study conducted in mice.
Immune T-cell response may help detect Parkinson’s earlier: Study
People in the prodromal, or presymptomatic, stage of Parkinson’s disease show increased immune activity, with T cells targeting the proteins PINK1 and alpha-synuclein at levels similar to those seen in patients already diagnosed with the neurodegenerative condition, a new study reports. These two proteins — PINK1 and alpha-synuclein — are key components of Lewy bodies, the abnormal protein clumps, or aggregates, implicated in the progressive los…
A protein with a double job against neurodegeneration - Global Happenings
Discovered theUnexpected double work of a protein crucial for cells, called DDX11: in addition to playing the role of the mechanic in the nucleus of the cell, where opens the double propeller of the DNA To allow it to replication and the repairalso works as a cytoplasm for cytoplasm for region The waste recycling. This is indicated by the study conducted by the Institute of Biochemistry and Cellular Biology of the National Research Council in co…
Coverage Details
Bias Distribution
- 100% of the sources are Center
To view factuality data please Upgrade to Premium